Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13,155,511
-
Total 13F shares
-
7,843,040
-
Share change
-
-412,018
-
Total reported value
-
$39,137,186
-
Price per share
-
$4.99
-
Number of holders
-
35
-
Value change
-
-$2,087,558
-
Number of buys
-
12
-
Number of sells
-
14
Institutional Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q2 2025
As of 30 Jun 2025 Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) had 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 7,843,040 shares of stock of the company.
Largest 10 holders included BVF INC/IL, Nantahala Capital Management, LLC, ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Affinity Asset Advisors, LLC, Deep Track Capital, LP, Commodore Capital LP, TCG Crossover Management, LLC, BANK OF AMERICA CORP /DE/, and RWA WEALTH PARTNERS, LLC.
This table shows 35 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.